Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis
|
|
- Adelia Shaw
- 6 years ago
- Views:
Transcription
1 DOI: /brain/awg038 Brain (2003), 126, 433±437 Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis M. Filippi, 1 M. Bozzali, 1 M. Rovaris, 1 O. Gonen, 5 C. Kesavadas, 3 A. Ghezzi, 4 V. Martinelli, 2 R. I. Grossman, 5 G. Scotti, 3 G. Comi, 2 and A. Falini 3 1 Neuroimaging Research Unit, Department of Neuroscience Departments of 2 Neurology and 3 Neuroradiology, Scienti c Institute and University Ospedale San Raffaele, Milan 4 Multiple Sclerosis Center, Ospedale di Gallarate, Gallarate, Italy and 5 Department of Radiology, New York University School of Medicine, New York, NY, USA Summary Although axonal pathology is recognized as one of the major pathological features of multiple sclerosis, it is less clear how early in its course it occurs and how it correlates with MRI-visible lesion loads. To assess this early axonal pathology, we quanti ed the concentration of whole-brain N-acetylaspartate (WBNAA) in a group of patients at the earliest clinical stage of the disease and compared the results with those from healthy controls. Conventional brain MRI and WBNAA using unlocalized proton magnetic resonance spectroscopy were obtained from 31 patients at presentation with clinically isolated syndromes suggestive of multiple sclerosis and paraclinical evidence of dissemination in space, and from 16 matched controls. An additional conventional MRI scan was obtained in all patients 4±6 months later to detect dissemination of lesions in time. Correspondence to: Dr Massimo Filippi, Neuroimaging Research Unit, Department of Neuroscience, Scienti c Institute and University, Ospedale San Raffaele, Via Olgettina 60, Milan, Italy m. lippi@hsr.it The mean WBNAA concentration was signi cantly lower in patients compared with the controls (P < ). It was not signi cantly different between patients with and without enhancing lesions at the baseline MRI or between patients with and without lesion dissemination in time. No correlation was found between WBNAA concentrations and lesion volumes. Widespread axonal pathology, largely independent of MRI-visible in ammation and too extensive to be completely reversible, occurs in patients even at the earliest clinical stage of multiple sclerosis. This nding lessens the validity of the current concept that the axonal pathology of multiple sclerosis is the end-stage result of repeated in ammatory events, and argues strongly in favour of early neuroprotective intervention. Keywords: multiple sclerosis; magnetic resonance imaging; magnetic resonance spectroscopy; whole-brain N-acetylaspartate; axonal pathology Abbreviations: EDSS = Expanded Disability Status Scale; Gd = gadolinium; 1 H-MRS = proton MR spectroscopy; MR = magnetic resonance; NAA = N-acetylaspartate; PD = proton-density; SE = spin-echo; SIENA = structural image evaluation, using normalization, of atrophy; VOI = volume of interest; WBNAA = whole-brain N-acetylaspartate Introduction Axonal pathology has been known to occur in multiple sclerosis from the earliest post-mortem descriptions of the disease (Charcot, 1868). Recent pathological studies have con rmed that irreversible axonal loss is a prominent feature of the disease (Ferguson et al., 1997; Trapp et al., 1998; van Waesberghe et al., 1999; Evangelou et al., 2000; Peterson et al., 2001), and the extensive in vivo application of quantitative magnetic resonance (MR) techniques has led to a general appreciation that axonal loss contributes signi cantly to the development of ` xed' disability in multiple ã Guarantors of Brain 2003 sclerosis patients (Davie et al., 1995; De Stefano et al., 1995, 1998; Trapp et al., 1999; Filippi, 2001). However, it is less clear how early in the course of the disease this axonal damage occurs and how it relates to the MRI-visible lesion load. Proton magnetic resonance spectroscopy ( 1 H-MRS) enables us to quantify axonal injury and loss through the measurement of changes in the signal intensity of N-acetylaspartate (NAA) (Davie et al., 1995; De Stefano et al., 1995, 1998), a metabolite localized almost exclusively
2 434 M. Filippi et al. to neurons and neuronal processes (Simmons et al., 1991). Localized 1 H-MRS studies have shown reduced NAA in T 2 -visible lesions (Arnold et al., 1994; Davie et al., 1994, 1997; De Stefano et al., 1995; Narayana et al., 1998), normalappearing white matter (NAWM) (Davie et al., 1995; De Stefano et al., 1998; Fu et al., 1998; Narayana et al., 1998; Kapeller et al., 2001) and grey matter (Kapeller et al., 2001) of patients with clinically de nite multiple sclerosis. Unfortunately, current 1 H-MRS is restricted to small volumes of interest (VOI), which typically represent <100 ml of the brain. Since multiple sclerosis is a diffuse disease of the CNS (Trapp et al., 1999; Filippi, 2001), estimates of the extent of axonal pathology from such measurements must rely on the unproven assumption that changes in NAA in the VOI accurately re ect the status of the entire brain. The volume restriction of localized 1 H-MRS has recently been overcome with a new unlocalized 1 H-MRS sequence which makes it possible to quantify the concentration of NAA from the whole brain (WBNAA) (Gonen et al., 1998, 2000), providing an overall assessment of the total load of the disease both within and outside MRI-visible lesions. To gain insight into the nature of axonal pathology in multiple sclerosis, we quanti ed WBNAA from a group of patients at the earliest clinical stage of multiple sclerosis (McDonald et al., 2001) and correlated it with the MRI-visible lesion loads. Material and methods Patients We studied 31 consecutive patients (23 women, eight men, mean age 28.7 years, SD 6.0 years) at presentation with clinically isolated syndromes suggestive of multiple sclerosis and paraclinical evidence of dissemination in space (McDonald et al., 2001). All patients were assessed within 3 months from the onset of the clinical symptoms (mean 26 days). The presenting symptoms were optic neuritis, brainstem syndromes and spinal cord syndromes in 10, 12 and nine patients, respectively. All alternative neurological diseases were excluded by appropriate investigations (McDonald et al., 2001). Oligoclonal bands were found in the CSF of 26 patients. Before MR acquisition, but on the same day, each patient underwent a full neurological assessment performed by a single observer who was blind to the MRI and WBNAA results. Disability was rated using the Expanded Disability Status Scale (EDSS) score (Kurtzke, 1983), which had a median of 0.0 (range 0.0±2.0) in this cohort. None of the patients had been treated with corticosteroids within the previous month. To demonstrate the presence of new lesions, and hence the dissemination in time of the disease (McDonald et al., 2001), all patients were followed up both clinically and with a second MRI 4±6 months after the rst. Sixteen healthy volunteers (12 women, four men; mean age 29.7 years; SD 4.5 years), with no history of neurological dysfunction and a normal neurological examination, served as controls. We obtained approval from The Fondazione San Raffael Ethics Committee and written informed consent from each subject before study initiation. MR acquisition First session 1 H-MRS and MRI were performed using a 1.5 T scanner (Vision; Siemens, Erlangen, Germany). The following sequences were collected from all subjects during a single MR session: (i) WBNAA 1 H-MRS based on the method described by Gonen et al. (2000); (ii) dual-echo turbo spinecho (SE) [repetition time (TR) 3300 ms; rst echo time (TE) 16 ms; second echo TE 98 ms; echo-train length 5; 24 contiguous 5 mm thick axial slices with a matrix and a mm 2 eld of view]; (iii) T 1 -weighted conventional SE (TR 768 ms, TE 14 ms, 24 contiguous 5 mm thick axial slices with a matrix and a mm 2 eld of view) before and after the administration of 0.1 mmol/kg of gadolinium (Gd). Second session Patients were repositioned using ad hoc guidelines (Miller et al., 1991). Dual-echo turbo SE and T 1 -weighted conventional SE before and after administration of 0.1 mmol/kg of Gd were obtained in a single session using the same acquisition procedures as those used previously. MRI analysis Dual-echo hard copies were revised in random order by two observers who did not know who the scans belonged to. Lesions were identi ed and marked by consensus on the proton-density (PD) and post-contrast T 1 -weighted scans. T 2 -weighted and precontrast T 1 -weighted images were always used to increase con dence in lesion identi cation. The number and location of T 2 -hyperintense and Gd-enhancing lesions were evaluated, and the ful lment of MRI criteria for multiple sclerosis diagnosis was assessed (McDonald et al., 2001). Then all images were transferred to an of ine workstation (Sun Sparcstation; Sun Microsystems, Mountain View, CA, USA) for lesion volume assessment by a single observer, again unaware of who the scans belonged to. This procedure used a segmentation technique based on signal intensity thresholding and characterized by high intra-rater reproducibility (Rovaris et al., 1997). In patients, changes in normalized brain volume over the follow-up period were also measured using a fully automated and accurate method, SIENA (structural image evaluation, using normalization, of atrophy) (Smith et al., 2001). SIENA performs segmentation of brain from nonbrain tissue in the head, estimates the outer skull surface (for two time points), and uses these results to register the two
3 Axonal damage in early multiple sclerosis 435 images while correcting for imaging geometry changes. Then the registered segmented brain images are used to estimate percentage changes in normalized brain volume (Smith et al., 2001). WBNAA 1 H-MRS analysis The 1 H-MRS data from each subject and from the reference phantom were transferred to the workstation and processed of ine with our custom software (IDL; Research Systems, Boulder, CO, USA). The NAA peak area was integrated by two operators unaware of the subject's identity (Gonen et al., 1998, 2000). It was converted into an absolute amount (in mmol) by scaling against the area of the signal from the reference phantom which contained 15 mmol NAA (5 mm) in water (Gonen et al., 1998, 2000). To correct for the considerable natural interindividual variation in brain size, the absolute amount of NAA from each individual was divided by their brain volume. For this purpose, absolute rather than normalized brain volumes were needed. Brain volumes were measured using a seed-growing technique based on signal intensity thresholding, as described extensively elsewhere (Rovaris et al., 2000). This yielded an absolute WBNAA concentration, in mm, which could be compared cross-sectionally (Gonen et al., 2000). Statistical analysis Differences in WBNAA concentrations between individual groups of subjects were assessed using the Mann±Whitney test. To correct for multiple comparisons, only P values <0.01 were considered signi cant (Bonferroni correction). Univariate correlations were assessed using the Spearman rank correlation coef cient. Results No abnormalities were seen on any of the conventional MRI scans from the controls. By de nition, all patients had paraclinical evidence of dissemination in space; in 19 this was demonstrated by MRI alone and in the remaining 12 by the combination of MRI ndings and the presence of oligoclonal bands in the CSF (McDonald et al., 2001). One or more enhancing lesions were seen in eight patients (seven had 1 and one had 7 enhancing lesions). From the clinical and MRI follow-up data, 16 patients met McDonald's criteria for lesion dissemination in time (McDonald et al., 2001). The average WBNAA concentration was mm (standard error 0.58 mm) in controls and mm (standard error 0.43 mm) in patients (P < ). Speci cally, the patients showed, on average, a 22.3% decrease in NAA concentration in the whole-brain parenchyma. No signi cant difference was found (P = 0.17) in average WBNAA concentration between patients with dissemination in space shown by MRI alone (mean 9.82 mm, standard error 0.57 mm) and those in whom a combination of MRI and CSF ndings was needed to demonstrate dissemination in space (McDonald et al., 2001) (mean mm, standard error 0.61 mm). Average WBNAA concentration also did not differ signi cantly (P = 0.27) between patients with (mean 9.32 mm, standard error 0.67 mm) and without (mean mm, standard error 0.53 mm) enhancing lesions on the baseline MRI. No correlation was found between WBNAA concentrations and lesion volume (WBNAA versus T 2 lesion volume, r = ±0.18; WBNAA versus T 1 -hypointense lesion volume, r = 0.05). The mean brain volume and the average WBNAA concentrations did not differ (P = 0.57) between patients ful lling McDonald's criteria at follow-up (mean 9.78 mm, standard error 0.59 mm) and those who did not (mean mm, standard error 0.62 mm). Between the rst and the second MRI sessions, a mean 0.27% (standard error 0.16%) decrease in normalized brain volume was observed in the patients. Considering the length of the follow-up (average 4.7 months), this gure corresponds to an average annualized percentage decrease in normalized brain volume of 0.69%. Discussion The NAA loss indicates that axonal pathology is an early event in the course of multiple sclerosis and ts with the demonstration that brain atrophy occurs at a relatively fast rate in patients with early multiple sclerosis (Rudick et al, 1999; Brex et al., 2000). This observation is corroborated by the nding of an average annualized percentage decrease of normalized brain volume of about 0.7%, a gure that closely matches those reported in patients with more advanced disease (Filippi and Grossman, 2002). Admittedly, not all the patients in this study met McDonald's criteria for an early diagnosis of multiple sclerosis (McDonald et al., 2001). Nevertheless, alternative diagnoses were carefully excluded and all had clinical pictures suggestive of multiple sclerosis at presentation. They were also selected for having a dissemination in space at presentation, i.e. MRI and/or CSF ndings consistent with a diagnosis of multiple sclerosis (McDonald et al., 2001). As a consequence, we believe that all of them are at high risk of ultimately progressing to clinically de nite multiple sclerosis (Brex et al., 2002). With this in mind, the rst issue to be addressed is how much of the observed WBNAA decrease is irreversible. Partially reversible NAA reductions in T 2 -visible lesions (Davie et al., 1994; De Stefano et al., 1995; Narayana et al., 1998) and NAWM (De Stefano et al., 1999) of multiple sclerosis patients have been described and attributed to possible recovery from sublethal axonal injury following resolution of in ammatory changes. Consequently, the reduced WBNAA concentrations in these patients could be interpreted as a transient functional axonal impairment secondary to in ammatory changes associated with the recent clinical attack. Indeed, we found that patients with at least one enhancing lesion, indicative of increased blood±brain barrier permeability and associated in ammation (Katz et al., 1993), had a lower average WBNAA than those with an inactive
4 436 M. Filippi et al. MRI scan. Nevertheless, the average WBNAA reduction in the latter group of patients was still remarkable (19.9%) compared with the matched controls. Although a certain amount of in ammation is known to go undetected on conventional MRI with the standard Gd dose (Filippi et al., 1998), we believe it is unlikely that this `occult' in ammatory component could lead to such a substantial WBNAA decrease. Therefore, we interpret such `NAA loss without MRI-visible in ammation' as an indication that at least a considerable portion of the axonal pathology is permanent, even this early in the clinical course of the disease. The next question relates to the relative contributions of MRI-visible lesions and occult damage in the normalappearing tissue to the reduced WBNAA concentrations in these patients. Since average T 2 lesion volume at this early stage of the disease is negligible (<1% fraction of the brain volume; on average, 2.6 versus 1165 ml) the decrease of >20% in WBNAA in the patients must be accounted for by widespread axonal damage in the NAWM alone or in association with neuronal injury in the grey matter. Our results disagree with those of a previous study (Brex et al., 1999), which was unable to detect a signi cant reduction in NAA concentration in the NAWM from patients with clinically isolated syndromes suggestive of multiple sclerosis. This discrepancy is likely to result from the fact that Brex et al. (1999) did not select patients for having a dissemination in space at presentation (McDonald et al., 2001) and, most importantly, because their NAA concentrations were based on VOIs with a mean volume of 2.64 ml, which were positioned in various white matter areas according to the distribution of T 2 -visible lesions. On the contrary, our interpretation of the results of the present study is in agreement with the demonstration of reduced central brain NAA/creatine (Cr) resonance intensity ratios in patients with early and non-disabling relapsing±remitting multiple sclerosis (De Stefano et al., 2001). Interestingly, in the study by De Stefano et al. (2001), NAA/Cr ratios were derived from VOIs much larger than those used by Brex et al. (1999), and T 2 -visible lesions accounted for only ~6% of the VOI. This interpretation is also consistent with post-mortem data showing decreased axonal density in the NAWM (Trapp et al., 1998; van Waesberghe et al., 1999; Evangelou et al., 2000) and the presence of cortical lesions associated with apoptotic loss of neurons, and axonal and dendritic transections (Peterson et al., 2001) in patients with long-standing multiple sclerosis. The novelty of this study is to show that axonal/neuronal damage can occur very early in the course of multiple sclerosis, when de nitive histopathological data are unlikely ever to be obtained. The lack of correlation between lesion volumes and WBNAA loss also suggests that neuronal/ axonal damage in the normal-appearing tissue at this earliest stage of multiple sclerosis occurs by mechanisms mostly independent of the axonal transection known to occur within in amed white-matter multiple sclerosis lesions (Ferguson et al., 1997; Trapp et al., 1998). In conclusion, this study suggests that signi cant irreversible axonal damage occurs in patients at the earliest stage of multiple sclerosis. This, together with the recognition that MRI-detectable in ammation is only indirectly linked to the neuronal/axonal damage in these patients should prompt the development and use of treatments capable of neuroprotective action. Acknowledgements This study was supported by a grant from the Italian Ministry of Health (contract ICS030.5/RF00.79), an unrestricted educational grant from Teva Pharmaceutical and NIH grants NS33385, NS37739 and NS References Arnold DL, Riess GT, Matthews PM, Francis GS, Collins DL, Wolfson C, et al. Use of proton magnetic resonance spectroscopy for monitoring disease progression in multiple sclerosis. Ann Neurol 1994; 36: 76±82. Brex PA, Gomez-Anson B, Parker GJ, Molyneux PD, Miszkiel KA, Barker GJ, et al. Proton MR spectroscopy in clinically isolated syndromes suggestive of multiple sclerosis. J Neurol Sci 1999; 166: 16±22. Brex PA, Jenkins R, Fox NC, Crum WR, O'Riordan JI, Plant GT, et al. Detection of ventricular enlargement in patients at the earliest clinical stage of MS. Neurology 2000; 54: 1689±91. Brex PA, Ciccarelli O, O'Riordan JI, Sailer M, Thompson AJ, Miller DH. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. New Engl J Med 2002; 346: 158±64. Charcot JM. Histologie de la scleârose en plaque. Gaz Hop (Paris) 1868; 141: 554±8. Davie CA, Hawkins CP, Barker GJ, Brennan A, Tofts PS, Miller DH, et al. Serial proton magnetic resonance spectroscopy in acute multiple sclerosis lesions. Brain 1994; 117: 49±58. Davie CA, Barker GJ, Webb S, Tofts PS, Thompson AJ, Harding AE, et al. Persistent functional de cit in multiple sclerosis and autosomal dominant cerebellar ataxia is associated with axon loss. Brain 1995; 118: 1583±92. Davie CA, Barker GJ, Thompson AJ, Tofts PS, McDonald WI, Miller DH. 1H magnetic resonance spectroscopy of chronic cerebral white matter lesions and normal appearing white matter in multiple sclerosis. J Neurol Neurosurg Psychiatry 1997; 63: 736±42. De Stefano N, Matthews PM, Antel J, Preul M, Francis GS, Arnold DL. Chemical pathology of acute demyelinating lesions and its correlation with disability. Ann Neurol 1995; 38: 901±9. De Stefano N, Matthews PM, Fu L, Narayanan S, Stanley J, Francis GS, et al. Axonal damage correlates with disability in patients with relapsing-remitting multiple sclerosis. Results of a longitudinal magnetic resonance spectroscopy study. Brain 1998; 121: 1469±77. De Stefano N, Narayanan S, Matthews PM, Francis GS, Antel JP, Arnold DL. In vivo evidence for axonal dysfunction remote from
5 Axonal damage in early multiple sclerosis 437 focal cerebral demyelination of the type seen in multiple sclerosis. Brain 1999; 122: 1933±9. De Stefano N, Narayanan S, Francis GS, Arnaoutelis R, Tartaglia MC, Antel JP, et al. Evidence of axonal damage in the early stages of multiple sclerosis and its relevance to disability. Arch Neurol 2001; 58: 65±70. Evangelou N, Konz D, Esiri MM, Smith S, Palace J, Matthews PM. Regional axonal loss in the corpus callosum correlates with cerebral white matter lesion volume and distribution in multiple sclerosis. Brain 2000; 123: 1845±9. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997; 120: 393±9. Filippi M. Linking structural, metabolic and functional changes in multiple sclerosis. [Review]. Eur J Neurol 2001; 8: 291±7. Filippi M, Grossman RI. MRI techniques to monitor MS evolution. The present and the future. [Review]. Neurology 2002; 58: 1147±53. Filippi M, Rovaris M, Capra R, Gasperini C, Yousry TA, Sormani MP, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-dtpa for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. Brain 1998; 121: 2011±20. Fu L, Matthwes PM, De Stefano N, Worsley KJ, Narayanan S, Francis GS, et al. Imaging axonal damage of normal-appearing white matter in multiple sclerosis. Brain 1998; 121: 103±13. Gonen O, Viswanathan AK, Catalaa I, Babb J, Udupa J, Grossman RI. Total brain N-acetylaspartate concentration in normal, agegrouped females: quantitation with non-echo proton NMR spectroscopy. Magn Reson Med 1998; 40: 684±9. Gonen O, Catalaa I, Babb JS, Ge Y, Mannon LJ, Kolson DL, et al. Total brain N-acetylaspartate. A new measure of disease load in MS. Neurology 2000; 54: 15±9. Kapeller P, McLean MA, Grif n CM, Chard D, Parker GJ, Barker GJ, et al. Preliminary evidence for neuronal damage in cortical grey matter and in normal appearing white matter in short duration relapsing-remitting multiple sclerosis: a quantitative MR spectroscopic imaging study. J Neurol 2001; 248: 131±8. Katz D, Taubenberger JK, Cannella B, McFarlin DE, Raine CS, McFarland HF. Correlation between magnetic resonance imaging ndings and lesion development in chronic, active multiple sclerosis. Ann Neurol 1993; 34: 661±9. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983; 33: 1444±52. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121±7. Miller DH, Barkof F, Berry I, Kappos L, Scotti G, Thompson AJ. Magnetic resonance imaging in the monitoring treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 1991; 54: 683±8. Narayana PA, Doyle TJ, Lai D, Wolinsky JS. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann Neurol 1998; 43: 56±71. Peterson JW, Bo L, Mork S, Chang A, Trapp BD. Transected neurites, apoptotic neurons, and reduced in ammation in cortical multiple sclerosis lesions. Ann Neurol 2001; 50: 389±400. Rovaris M, Filippi M, Calori G, Rodegher M, Campi A, Colombo B, et al. Intra-observer reproducibility in measuring new putative MR markers of demyelination and axonal loss in multiple sclerosis: a comparison with conventional T2-weighted images. J Neurol 1997; 244: 266±70. Rovaris M, Inglese M, van Schijndel RA, Sormani MP, Rodegher M, Comi G, et al. Sensitivity and reproducibility of volume change measurements of different brain portions on magnetic resonance imaging in patients with multiple sclerosis. J Neurol 2000; 247: 960±5. Rudick RA, Fisher E, Lee JC, Simon J, Jacobs L. Use of the brain parenchymal fraction to measure whole brain atrophy in relapsingremitting MS. Multiple Sclerosis Collaborative Research Group. Neurology 1999; 53: 1698±704. Simmons ML, Frondoza CG, Coyle JT. Immunocytochemical localization of N-acetyl aspartate with monoclonal antibodies. Neuroscience 1991; 45: 37±45. Smith SM, De Stefano N, Jenkinson M, Matthews PM. Normalized accurate measurement of longitudinal brain change. J Comput Assist Tomogr 2001; 25: 466±75. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L. Axonal transection in the lesions of multiple sclerosis. New Engl J Med 1998; 338: 278±85. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. [Review]. Curr Opin Neurol 1999; 12: 295±302. van Waesberghe JH, Kamphorst W, De Groot CJ, van Walderveen MA, Castelijns JA, Ravid R, et al. Axonal loss in multiple sclerosis lesions: magnetic resonance imaging insights into substrates of disability. Ann Neurol 1999; 46: 747±54. Received August 6, Accepted September 9, 2002
ORIGINAL CONTRIBUTION. Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis
ORIGINAL CONTRIBUTION Axonal Injury and Overall Tissue Loss Are Not Related in Primary Progressive Multiple Sclerosis Marco Rovaris, MD; Antonio Gallo, MD; Andrea Falini, MD; Beatrice Benedetti, MD; Paolo
More informationEarly development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
DOI: 10.1093/brain/awh126 Brain (2004), 127, 1101±1107 Early development of multiple sclerosis is associated with progressive grey matter atrophy in patients presenting with clinically isolated syndromes
More informationPrimary progressive multiple sclerosis: a 5-year clinical and MR study
DOI: 10.1093/brain/awg261 Advanced Access publication August 5, 2003 Brain (2003), 126, 2528±2536 Primary progressive multiple sclerosis: a 5-year clinical and MR study G. T. Ingle, 1 V. L. Stevenson,
More informationMRI dynamics of brain and spinal cord in progressive multiple sclerosis
J7ournal of Neurology, Neurosurgery, and Psychiatry 1 996;60: 15-19 MRI dynamics of brain and spinal cord in progressive multiple sclerosis 1 5 D Kidd, J W Thorpe, B E Kendall, G J Barker, D H Miller,
More informationORIGINAL CONTRIBUTION. Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis
ORIGINAL CONTRIBUTION Magnetization Transfer Magnetic Resonance Imaging and Clinical Changes in Patients With Relapsing-Remitting Multiple Sclerosis Celia Oreja-Guevara, MD; Arnaud Charil, MSc; Domenico
More informationORIGINAL CONTRIBUTION. Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis. imaging (MRI) provides
ORIGINAL CONTRIBUTION Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis Bas Jasperse, MD; Arjan Minneboo, MD; Vincent de Groot, MD; Nynke F. Kalkers, MD, PhD; Paul E.
More informationRelevance of Hypointense Lesions on Fast Fluid- Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis
AJNR Am J Neuroradiol 20:813 820, May 1999 Relevance of Hypointense Lesions on Fast Fluid- Attenuated Inversion Recovery MR Images as a Marker of Disease Severity in Cases of Multiple Sclerosis Marco Rovaris,
More informationEvolution of T 1 black holes in patients with multiple sclerosis imaged monthly for 4 years
DOI: 10.1093/brain/awg182 Advanced Access publication June 23, 2003 Brain (2003), 126, 1782±1789 Evolution of T 1 black holes in patients with multiple sclerosis imaged monthly for 4 years Francesca Bagnato,
More informationABSTRACT Background In patients with isolated syndromes that are clinically suggestive of multiple sclerosis,
A LONGITUDINAL STUDY OF ABNORMALITIES ON MRI AND DISABILITY FROM MULTIPLE SCLEROSIS PETER A. BREX, M.D., OLGA CICCARELLI, M.D., JONATHON I. O RIORDAN, M.D., MICHAEL SAILER, M.D., ALAN J. THOMPSON, M.D.,
More informationNeuroradiology Original Research
MRI of Multiple Sclerosis Lesions Neuroradiology Original Research Ender Uysal 1 Sukru Mehmet Erturk 1 Hakan Yildirim 1 Feray Seleker 2 Muzaffer Basak 1 Uysal E, Erturk SM, Yildirim H, et al. Keywords:
More informationMagnetization-Transfer Histogram Analysis of the Cervical Cord in Patients with Multiple Sclerosis
AJNR Am J Neuroradiol 20:1803 1808, November/December 1999 Magnetization-Transfer Histogram Analysis of the Cervical Cord in Patients with Multiple Sclerosis Marco Bozzali, Maria A. Rocca, Giuseppe Iannucci,
More informationQuantitative divusion weighted magnetic resonance imaging, cerebral atrophy, and disability in multiple sclerosis
318 Division of Clinical Neurology, Faculty of Medicine, University Hospital, Queen s Medical Centre, Nottingham NG7 2UH, UK M Wilson X Lin B P Turner L D Blumhardt Division of Academic Radiology P S Morgan
More informationLong-Term Changes of Magnetization Transfer Derived Measures from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis
AJNR Am J Neuroradiol 20:821 827, May 1999 Long-Term Changes of Magnetization Transfer Derived Measures from Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis Maria A. Rocca,
More informationUse of MRI Technology in Determining Prognosis and Tracking Therapeutic Benefit in Multiple Sclerosis
Use of MRI Technology in Determining Prognosis and Tracking Therapeutic Benefit in Multiple Sclerosis Timothy Vollmer, MD Associate Professor of Neurology Yale School of Medicine New Haven, Connecticut
More informationORIGINAL CONTRIBUTION. Infratentorial Lesions Predict Long-term Disability in Patients With Initial Findings Suggestive of Multiple Sclerosis
ORIGINAL CONTRIBUTION Infratentorial Lesions Predict Long-term Disability in Patients With Initial Findings Suggestive of Multiple Sclerosis Arjan Minneboo, MD; Frederick Barkhof, MD; Chris H. Polman,
More informationProton Magnetic Resonance Spectroscopy
1432/Cap.10/2b 12-11-2001 16:55 Pagina 3 Chapter 10 Proton Magnetic Resonance Spectroscopy Z. CARAMANOS, A.C. SANTOS, S.J. FRANCIS, S. NARAYANAN, D. PELLETIER, D.L. ARNOLD Introduction Primary Progressive
More informationT he spinal cord is frequently affected, both pathologically
51 PAPER Increasing cord atrophy in early relapsing-remitting multiple sclerosis: a 3 year study W Rashid, G R Davies, D T Chard, C M Griffin, D R Altmann, R Gordon, A J Thompson, D H Miller... See end
More informationSingle-Dose Gadolinium with Magnetization Transfer versus Triple- Dose Gadolinium in the MR Detection of Multiple Sclerosis Lesions
Single-Dose Gadolinium with Magnetization Transfer versus Triple- Dose Gadolinium in the MR Detection of Multiple Sclerosis Lesions J. H. T. M. van Waesberghe, J. A. Castelijns, W. Roser, N. Silver, T.
More informationMRI in MS: the radiologist perspective
MS Preceptorship - Updating Knowledge in Multiple Sclerosis - June, 1-3 2010 Barcelona MRI in MS: the radiologist perspective Àlex Rovira Unidad de Resonancia Magnética Servicio de Radiología Hospital
More informationMagnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis
doi:10.1093/brain/awh654 Brain (2005), 128, 2911 2925 Magnetization transfer histograms in clinically isolated syndromes suggestive of multiple sclerosis K. T. M. Fernando, 1,3 D. J. Tozer, 1 K. A. Miszkiel,
More informationgadolinium-dtpa for detection of MRI
540 50ournal ofneurology, Neurosurgery, and Psychiatry 1995;59:540-544 SHORT REPORT Neurology M Filippi V Martinelli B Colombo N Canal G Comi Neuroradiology, Scientific Institute Ospedale San Raffaele,
More informationMultiple sclerosis (MS) is a disabling chronic demyelinating disease
Diagn Interv Radiol 2010; 16:106 111 Turkish Society of Radiology 2010 NEURORADIOLOGY ORIGINAL ARTICLE Imaging of active multiple sclerosis plaques: efficiency of contrast-enhanced magnetization transfer
More informationMagnetic resonance imaging in multiple sclerosis
APRIL 2002 103 Magnetic resonance imaging in multiple sclerosis Beside the ability to detect the Olga Ciccarelli and David H. Miller NMR Unit, Institute of Neurology, University College London, Queen Square,
More informationClinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets
494 Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San RaVaele, University of Milan, Via Olgettina 6, 2132 Milan, Italy M P Sormani M Rovaris M Filippi Clinical Trials
More informationORIGINAL CONTRIBUTION. Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study
ORIGINAL CONTRIBUTION Magnetic Resonance Imaging Effects of Interferon in the BENEFIT Study Integrated 2-Year Results Frederik Barkhof, MD, PhD; Chris H. Polman, MD, PhD; Ernst-Wilhelm Radue, MD; Ludwig
More informationORIGINAL CONTRIBUTION. Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis
ORIGINAL CONTRIBUTION Normal-Appearing Brain T1 Relaxation Time Predicts Disability in Early Primary Progressive Multiple Sclerosis Francesco Manfredonia, MD; Olga Ciccarelli, PhD; Zhaleh Khaleeli, MRCP;
More informationMagnetization Transfer and Diffusion Tensor MR Imaging of Acute Disseminated Encephalomyelitis
AJNR Am J Neuroradiol 23:267 272, February 2002 Magnetization Transfer and Diffusion Tensor MR Imaging of Acute Disseminated Encephalomyelitis Matilde Inglese, Fabrizio Salvi, Giuseppe Iannucci, Gian Luigi
More informationA Comparison of MR Imaging with Fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR Sequences in the Assessment of Patients with Multiple Sclerosis
AJNR Am J Neuroradiol 20:1931 1938, November/December 1999 A Comparison of MR Imaging with Fast-FLAIR, HASTE-FLAIR, and EPI-FLAIR Sequences in the Assessment of Patients with Multiple Sclerosis Massimo
More informationMRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS
MRI MARKERS TO UNDERSTAND PROGRESSION MECHANISMS Maria A. Rocca Neuroimaging Research Unit, Institute of Experimental Neurology, Division of Neuroscience, San Raffaele Scientific Institute, Vita-Salute
More informationMagnetization transfer can predict clinical evolution in patients with multiple sclerosis
J Neurol (2002) 249 : 662 668 10.1007/s00415-002-0686-4 ORIGINAL COMMUNICATION A. Carlos Santos Sridar Narayanan Nicola de Stefano M. Carmela Tartaglia Simon J. Francis Rozie Arnaoutelis Zografos Caramanos
More information1 MS Lesions in T2-Weighted Images
1 MS Lesions in T2-Weighted Images M.A. Sahraian, E.-W. Radue 1.1 Introduction Multiple hyperintense lesions on T2- and PDweighted sequences are the characteristic magnetic resonance imaging (MRI) appearance
More informationMultiple sclerosis (MS) is an inflammatory disease of the central nervous. Magnetic Resonance Imaging in Multiple Sclerosis
DIAGNOSIS AND MANAGEMENT UPDATE Magnetic Resonance Imaging in Multiple Sclerosis Salvatore Q. Napoli, MD, * Rohit Bakshi, MD * *Partners, Multiple Sclerosis Center, Boston, MA, Center for Neurological
More informationProton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders
(2000) 6, Suppl 2, S121 ± S129 ã 2000, Inc. www.jneurovirol.com Proton MR spectroscopy to assess axonal damage in multiple sclerosis and other white matter disorders Nicola De Stefano*,1, Sridar Narayanan
More informationEFNS guidelines on the use of neuroimaging in the management of multiple sclerosis
European Journal of Neurology 2006, 13: 313 325 EFNS TASK FORCE ARTICLE/CME ARTICLE EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis M. Filippi a, M. A. Rocca a, D. L.
More informationShort-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis
AJNR Am J Neuroradiol 24:75 81, January 2003 Short-Term Correlations between Clinical and MR Imaging Findings in Relapsing-Remitting Multiple Sclerosis Marco Rovaris, Giancarlo Comi, David Ladkani, Jerry
More informationORIGINAL CONTRIBUTION. Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic
ORIGINAL CONTRIBUTION Reliability of Classifying Multiple Sclerosis Disease Activity Using Magnetic Resonance Imaging in a Multiple Sclerosis Clinic Ebru Erbayat Altay, MD; Elizabeth Fisher, PhD; Stephen
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org How
More informationMultiple sclerosis (MS) is considered an inflammatory autoimmune
REVIEW ARTICLE Multiple Sclerosis: The Role of MR Imaging Y. Ge SUMMARY: MR offers by far the most sensitive technique for detecting multiple sclerosis (MS) lesions and has proved to be an important paraclinical
More informationIn vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study
doi:10.1093/brain/awm110 Brain (2007), 130, 2211^2219 In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study F. Agosta, 1,2 M. Absinta, 1,2 M. P. Sormani,
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis That Is Progressive From the Time of Onset
ORIGINAL CONTRIBUTION Multiple Sclerosis That Is Progressive From the Time of Onset Clinical Characteristics and Progression of Disability P. B. Andersson, MBChB, DPhil; E. Waubant, MD; L. Gee, MPH; D.
More informationMagnetic Resonance Imaging and Spectroscopy: Insights into the Pathology and Pathophysiology of Multiple Sclerosis.
Chapter 10 (pp 139-167) of Multiple Sclerosis 2 - Blue Books of Practical Neurology, vol. 27. J.H Noseworthy, W.I. McDonald (eds.). Elsevier Science (USA), 2003. Magnetic Resonance Imaging and Spectroscopy:
More informationFocal thinning of the cerebral cortex in multiple sclerosis
DOI: 10.1093/brain/awg175 Advanced Access publication June 4, 2003 Brain (2003), 126, 1734±1744 Focal thinning of the cerebral cortex in multiple sclerosis Michael Sailer, 1 Bruce Fischl, 2,3 David Salat,
More informationEvolution of Multiple Sclerosis Lesions on Serial Contrast-Enhanced T1-Weighted and Magnetization-Transfer MR Images
AJNR Am J Neuroradiol 20:1939 1945, November/December 1999 Evolution of Multiple Sclerosis Lesions on Serial Contrast-Enhanced T1-Weighted and Magnetization-Transfer MR Images Alex Rovira, Juli Alonso,
More informationAbsolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normalappearing white matter of multiple sclerosis patients
Brain (1999), 122, 513 521 Absolute quantification of brain metabolites by proton magnetic resonance spectroscopy in normalappearing white matter of multiple sclerosis patients P. Sarchielli, 1 O. Presciutti,
More informationAssociation of asymptomatic spinal cord lesions and atrophy with disability. 5 years after a clinically isolated syndrome
Association of asymptomatic spinal cord lesions and atrophy with disability 5 years after a clinically isolated syndrome WJ Brownlee 1, DR Altmann 1,2, P Alves Da Mota 1, JK Swanton 1, KA Miszkiel 3, CAM
More informationStefan Ropele, Siegried Strasser-Fuchs, Michael Augustin, Rudolf Stollberger, Christian Enzinger, Hans-Peter Hartung, and Franz Fazekas
AJNR Am J Neuroradiol 21:1885 1891, November/December 2000 A Comparison of Magnetization Transfer Ratio, Magnetization Transfer Rate, and the Native Relaxation Time of Water Protons Related to Relapsing-remitting
More informationAssessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosis
Assessment and optimisation of MRI measures of atrophy as potential markers of disease progression in multiple sclerosis Thesis submitted for the degree of Doctor of Philosophy Valerie Anderson UCL Institute
More informationMDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial
MDWISE PRIOR AUTHORIZATION CRITERIA TYSABRI (natalizumab): 300mg/15mL single use vial Formulary Status: Non-Formulary requiring prior authorization PA CRITERIA FOR INITIAL AUTHORIZATION FOR USE IN MULTIPLE
More informationCorpus callosum index and long-term disability in multiple sclerosis patients
J Neurol (2010) 257:1256 1264 DOI 10.1007/s00415-010-5503-x ORIGINAL COMMUNICATION Corpus callosum index and long-term disability in multiple sclerosis patients Özgür Yaldizli Ramin Atefy Achim Gass Dietrich
More informationMagnetic Resonance Spectroscopic Findings of Chronic Lesions in Two Subtypes of Multiple Sclerosis: Primary Progressive Versus Relapsing Remitting
Iranian Journal of Radiology. 2013 September; 10(3): 128-32. Published Online 2013 August 30. NEURORADIOLOGY 10.5812/iranjradiol.11336 Research Article Magnetic Resonance Spectroscopic Findings of Chronic
More informationMassimo Filippi * 1. Introduction
Journal of the Neurological Sciences 206 (2003) 157 164 www.elsevier.com/locate/jns MRI clinical correlations in the primary progressive course of MS: new insights into the disease pathophysiology from
More informationChanges in the normal appearing brain tissue and cognitive impairment in multiple sclerosis
J Neurol Neurosurg Psychiatry 2000;68:157 161 157 Neuroimaging Research Unit, Department of Neuroscience, Scientific Institute Ospedale San RaVaele, Milan, Italy M Filippi C Tortorella M Rovaris M Bozzali
More informationADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis lesion heterogeneity, as demonstrated by quantitative MRI
2074MSJ19610.1177/1352458512462074Multiple Sclerosis JournalYiannakas et al. Research Paper MULTIPLE SCLEROSIS JOURNAL MSJ ADvanced IMage Algebra (ADIMA): a novel method for depicting multiple sclerosis
More informationMULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson
MULTIPLE SCLEROSIS IN 2015 Managing the complexity of multiple sclerosis Olga Ciccarelli and Alan Thompson The application of imaging biomarkers has provided new insights into the mechanisms of damage
More informationN-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry
J Neurol (2007) 254:631 637 DOI 10.1007/s00415-006-0415-5 ORIGINAL COMMUNICATION Bas Jasperse Cornelis Jakobs M. Judith Eikelenboom Christine D. Dijkstra Bernard M.J. Uitdehaag Frederik Barkhof Chris H.
More informationSupplementary Online Content
Supplementary Online Content Schlaeger R, Papinutto N, Zhu AH, et al. Association between thoracic spinal cord gray matter atrophy and disability in multiple sclerosis. JAMA Neurol. Published online June
More informationThe prognostic value of brain MRI in clinically isolated syndromes of the CNS A 10-year follow-up
Brain (1998), 121, 495 503 The prognostic value of brain MRI in clinically isolated syndromes of the CNS A 10-year follow-up J. I. O Riordan, 1 A. J. Thompson, 1 D. P. E. Kingsley, 2 D. G. MacManus, 1
More informationUniversity of Groningen. Fluoxetine as disease modifying treatment in multiple sclerosis Mostert, Jop Pieter
University of Groningen Fluoxetine as disease modifying treatment in multiple sclerosis Mostert, Jop Pieter IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationORIGINAL CONTRIBUTION. Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage
ORIGINAL CONTRIBUTION Multiple Sclerosis Lesions and Irreversible Brain Tissue Damage A Comparative Ultrahigh-Field Strength Magnetic Resonance Imaging Study Tim Sinnecker; Paul Mittelstaedt; Jan Dörr,
More informationThe Low Sensitivity of Fluid-Attenuated Inversion-Recovery MR in the Detection of Multiple Sclerosis of the Spinal Cord
The Low Sensitivity of Fluid-Attenuated Inversion-Recovery MR in the Detection of Multiple Sclerosis of the Spinal Cord Mark D. Keiper, Robert I. Grossman, John C. Brunson, and Mitchell D. Schnall PURPOSE:
More informationIsolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis
AJNR Am J Neuroradiol 21:702 706, April 2000 Isolated Demyelinating Syndromes: Comparison of Different MR Imaging Criteria to Predict Conversion to Clinically Definite Multiple Sclerosis Mar Tintoré, Alex
More informationPATIENTS WITH MULTIPLE SCLEROSIS
3 PATIENTS WITH MULTIPLE SCLEROSIS PREFER EARLY DIAGNOSIS Abstract The new diagnostic criteria for multiple sclerosis (MS) allow for a definite diagnosis in earlier stages of disease. Yet, clinicians may
More informationQuantification of Brain Damage in Cerebrotendinous Xanthomatosis with Magnetization Transfer MR Imaging
AJNR Am J Neuroradiol 24:495 500, March 2003 Quantification of Brain Damage in Cerebrotendinous Xanthomatosis with Magnetization Transfer MR Imaging Matilde Inglese, Nicola De Stefano, Elisabetta Pagani,
More informationFig. 1. Localized single voxel proton MR spectroscopy was performed along the long axis of right hippocampus after extension of patient s head to
125 A B C Fig. 1. Localized single voxel proton MR spectroscopy was performed along the long axis of right hippocampus after extension of patient s head to obtain entire dimension of the hippocampal body.
More informationTopics in Neuroscience
Topics in Neuroscience Managing Editor: GIANCARLO COMI Co-Editor: JACOPO MELDOLESI Associate Editors: MASSIMO FILIPPI LETIZIA LEOCANI GIANVITO MARTINO Early treatment in multiple sclerosis with intravenous
More informationORIGINAL ARTICLE Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis
(2015) 53, 520 525 & 2015 International Society All rights reserved 1362-4393/15 www.nature.com/sc ORIGINAL ARTICLE Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement
More informationIT HAS BECOME clear from results
ORIGINAL CONTRIBUTION Axonal Injury or Loss in the Internal Capsule and Motor Impairment in Multiple Sclerosis Martin A. Lee, MRCP; Andrew M. Blamire, PhD; Sarah Pendlebury, MRCP; King-Hee Ho, MD; Kerry
More informationSHORTLY AFTER ITS FIRST DEpiction
OBSERVATION Seven-Tesla Magnetic Resonance Imaging New Vision of Microvascular Abnormalities in Multiple Sclerosis Yulin Ge, MD; Vahe M. Zohrabian, MD; Robert I. Grossman, MD Background: Although the role
More informationMagnetic Resonance Spectroscopy of Memory and Frontal Brain Region in Early Multiple Sclerosis
Magnetic Resonance Spectroscopy of Memory and Frontal Brain Region in Early Multiple Sclerosis Wolfgang Staffen, M.D. Harald Zauner, Ph.D. Aldis Mair, M.D. Andrea Kutzelnigg, M.D. Peter Kapeller, M.D.
More informationMarchiafava-Bignami Disease: Longitudinal MR Imaging and MR Spectroscopy Study
AJNR Am J Neuroradiol 24:249 253, February 2003 Case Report Marchiafava-Bignami Disease: Longitudinal MR Imaging and MR Spectroscopy Study Anna Gambini, Andrea Falini, Lucia Moiola, Giancarlo Comi, and
More informationNIH Public Access Author Manuscript Arch Neurol. Author manuscript; available in PMC 2008 November 5.
NIH Public Access Author Manuscript Published in final edited form as: Arch Neurol. 2008 June ; 65(6): 812 816. doi:10.1001/archneur.65.6.812. 7T MRI: New Vision of Microvascular Abnormalities in Multiple
More informationMR imaging has played an important role in contributing
CONSENSUS STATEMENT Standardized MR Imaging Protocol for Multiple Sclerosis: Consortium of MS Centers Consensus Guidelines J.H. Simon D. Li A. Traboulsee P.K. Coyle D.L. Arnold F. Barkhof J.A. Frank R.
More informationEpidemiology, Diagnosis, Natural History & Clinical Course
Epidemiology, Diagnosis, Natural History & Clinical Course Multiple Sclerosis Immune-mediated, chronic, inflammatory disease precipitated by unknown environmental factors in genetically susceptible individuals
More informationORIGINAL CONTRIBUTION. Influence of Apolipoprotein E 4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis
ORIGINAL CONTRIBUTION Influence of Apolipoprotein E 4 Genotype on Brain Tissue Integrity in Relapsing-Remitting Multiple Sclerosis Nicola De Stefano, MD; Maria Letizia Bartolozzi, MD; Benedetta Nacmias,
More informationOvid: Barkhof: Neurology, Volume 49(6).December Copyright 1997 American Academy of Neurology. Volume 49(6) December 1997 pp
Page 1 of 11 Copyright 1997 American Academy of Neurology Volume 49(6) December 1997 pp 1682-1688 Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis [Articles]
More informationSpinal cord MR imaging in Multiple Sclerosis
43ème CONGRÈS ANNUEL de la Société Française de NeuroRadiologie 30 mars au 1 er avril 2016 Novotel Paris Tour Eiffel Spinal cord MR imaging in Multiple Sclerosis Àlex Rovira Unitat de Neurorradiología.
More informationComputer-Assisted Quantitation of Enhancing Lesions in Multiple Sclerosis: Correlation with Clinical Classification
Computer-Assisted Quantitation of Enhancing Lesions in Multiple Sclerosis: Correlation with Clinical Classification Yukio Miki, Robert I. Grossman, Jayaram K. Udupa, Supun Samarasekera, Mark A. van Buchem,
More informationEffects of Contrast Material on Single-volume Proton MR Spectroscopy
AJNR Am J Neuroradiol 21:1084 1089, June/July 2000 Effects of Contrast Material on Single-volume Proton MR Spectroscopy J. Keith Smith, Lester Kwock, and Mauricio Castillo BACKGROUND AND PURPOSE: Administration
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationMRI diagnostic criteria for multiple sclerosis: an update
MRI diagnostic criteria for multiple sclerosis: an update Poster No.: C-0285 Congress: ECR 2013 Type: Educational Exhibit Authors: L. Valls Masot, A. M. Quiles Granado, J. Puig Alcántara, L. RamióTorrentà,
More informationwith multiple sclerosis: a meta-analytic review
doi:10.1093/brain/awh640 Brain (2005), 128, 2483 2506 REVIEW ARTICLE 1 H-MRS quantification of tna and tcr in patients with multiple sclerosis: a meta-analytic review Zografos Caramanos, Sridar Narayanan
More informationFormation of lesions in multiple sclerosis (MS) comprises a
ORIGINAL RESEARCH D.S. Meier H.L. Weiner C.R.G. Guttmann MR Imaging Intensity Modeling of Damage and Repair In Multiple Sclerosis: Relationship of Short-Term Lesion Recovery to Progression and Disability
More informationImaging of Multiple Sclerosis: Role in Neurotherapeutics
NeuroRx : The Journal of the American Society for Experimental NeuroTherapeutics Imaging of Multiple Sclerosis: Role in Neurotherapeutics Rohit Bakshi,* Alireza Minagar, Zeenat Jaisani,* and Jerry S. Wolinsky
More informationSerial magnetization transfer imaging in acute optic neuritis
DOI: 10.1093/brain/awh076 Brain (2004), 127, 692±700 Serial magnetization transfer imaging in acute optic neuritis S. J. Hickman, 1,2 A. T. Toosy, 1,2 S. J. Jones, 3 D. R. Altmann, 1,4 K. A. Miszkiel,
More informationMEDIA BACKGROUNDER. Multiple Sclerosis: A serious and unpredictable neurological disease
MEDIA BACKGROUNDER Multiple Sclerosis: A serious and unpredictable neurological disease Multiple sclerosis (MS) is a complex chronic inflammatory disease of the central nervous system (CNS) that still
More informationCHAIR SUMMIT 7TH ANNUAL #CHAIR2014. Master Class for Neuroscience Professional Development. September 11 13, Westin Tampa Harbour Island
#CHAIR2014 7TH ANNUAL CHAIR SUMMIT Master Class for Neuroscience Professional Development September 11 13, 2014 Westin Tampa Harbour Island Sponsored by #CHAIR2014 Use of MRI in Clinical Decision- Making
More informationRegional Cervical Cord Atrophy and Disability in Multiple Sclerosis: A Voxel-based Analysis 1
Note: This copy is for your personal non-commercial use only. To order presentation-ready copies for distribution to your colleagues or clients, contact us at www.rsna.org/rsnarights. Paola Valsasina,
More informationMAGNIMS MRI in monitoring disease activity and progression
Teaching Course 3 MAGNIMS MRI in monitoring disease activity and progression Chairs: C. Enzinger (Graz, AT) N. De Stefano (Siena, IT) 7 Chances and challenges in monitoring disease activity and progression
More informationClinical, Laboratory and Radiological Predictors of Outcome in Relapsing Remitting Multiple Sclerosis
Ashraf A. Aboelsafa et al. Clinical, Laboratory and Radiological Predictors of Outcome in Relapsing Remitting Multiple Sclerosis Ashraf A. Aboelsafa, Ehab A. Elseidy, Ehab S. Mohammed Department of Neuropsychiatry,
More informationWhole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation
AJNR Am J Neuroradiol 25:985 996, June/July 2004 Whole-Brain Atrophy in Multiple Sclerosis Measured by Automated versus Semiautomated MR Imaging Segmentation Jitendra Sharma, Michael P. Sanfilipo, Ralph
More informationStandardized, Reproducible, High Resolution Global Measurements of T1 Relaxation Metrics in Cases of Multiple Sclerosis
AJNR Am J Neuroradiol 24:58 67, January 2003 Standardized, Reproducible, High Resolution Global Measurements of T1 Relaxation Metrics in Cases of Multiple Sclerosis Radhika Srinivasan, Roland Henry, Daniel
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 2, by the Massachusetts Medical Society VOLUME 343 N OVEMBER 16, 2 NUMBER 2 RELAPSES AND PROGRESSION OF DISABILITY IN MULTIPLE SCLEROSIS CHRISTIAN CONFAVREUX,
More informationNEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS
NEW DIAGNOSTIC CRITERIA FOR MULTIPLE SCLEROSIS Jeffrey A. Cohen, MD Director, Experimental Therapeutics Mellen MS Center Neurological Institute Cleveland Clinic 2018 Regional MS Summit 30 June 2018 Disclosures
More informationLOOKING AHEAD: THE FUTURE OF MULTIPLE SCLEROSIS* Amit Bar-Or, MD, FRCP(C), MSc PARADIGM SHIFTS AND EMERGING CONCEPTS
LOOKING AHEAD: THE FUTURE OF MULTIPLE SCLEROSIS* Amit Bar-Or, MD, FRCP(C), MSc ABSTRACT Multiple sclerosis (MS) is a complex condition, characterized by considerable variability in its presentation and
More informationClinically isolated syndromes (CIS) may
RECOGNIZING AND MANAGING THE CLINICALLY ISOLATED SYNDROME* Steven L. Galetta, MD ABSTRACT Clinically isolated demyelinating syndromes, such as optic neuritis, transverse myelitis, and brain-stem disorders,
More informationCADASIL: structural MR imaging changes and apolipoprotein E genotype S E V E N
CADASIL: structural MR imaging changes and apolipoprotein E genotype S E V E N CADASIL: structural MR imaging changes and apolipoprotein E genotype R. van den Boom S.A.J. Lesnik Oberstein A.A. van den
More informationJosé A Mendes-Ribeiro, Raquel Soares, Fernanda Simões-Ribeiro, M Luiza Guimarães
58 Neurophysiology Unit J A Mendes-Ribeiro M L Guimarães Department of Neurology and Neurosurgery, Hospital S João, Porto, Portugal F Simões-Ribeiro Magnetic Resonance Unit, IPO, Porto, Portugal R Soares
More informationThe Role of MRI in Multiple Sclerosis
September 2006 The Role of MRI in Multiple Sclerosis David Cochran, Harvard Medical School Year IV Meet our patient WM 49yoF presents to Multiple Sclerosis Clinic for follow-up regarding worsening symptoms
More informationORIGINAL CONTRIBUTION. Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging
ORIGINAL CONTRIBUTION Efficacy of Azathioprine on Multiple Sclerosis New Brain Lesions Evaluated Using Magnetic Resonance Imaging Luca Massacesi, MD; Alessandro Parigi, MD; Alessandro Barilaro, MD; Anna
More information